As described above, individuals with DS have a decreased risk of most solid tumors, a phenotype attributed to the triplosensitivity of specific genes on chromosome 21, such as ETS2, RCAN1, and DYRK1A. This evidence concerns the gene RCAN1 and Dravet syndrome.